{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:16:32Z","timestamp":1793070992692,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16GW0105"],"award-info":[{"award-number":["16GW0105"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.coviro.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T17:31:11Z","timestamp":1540834271000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-1014","authenticated-orcid":false,"given":"Daniel","family":"Todt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni Luise","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.10.001_bib0005","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1053\/j.gastro.2012.02.014","article-title":"Pathogenesis and treatment of hepatitis e virus infection","volume":"142","author":"Wedemeyer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.001_bib0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1099\/jgv.0.000393","article-title":"Proposed reference sequences for hepatitis E virus subtypes","volume":"97","author":"Smith","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0015","doi-asserted-by":"crossref","first-page":"17086","DOI":"10.1038\/nrdp.2017.86","article-title":"Hepatitis E virus infection","volume":"3","author":"Kamar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coviro.2018.10.001_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrgastro.2017.150","article-title":"Hepatitis E virus. Advances and challenges","volume":"15","author":"Nimgaonkar","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0025","doi-asserted-by":"crossref","first-page":"9838041","DOI":"10.1155\/2016\/9838041","article-title":"Hepatitis E virus in industrialized countries. the silent threat","volume":"2016","author":"Clemente-Casares","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.coviro.2018.10.001_bib0030","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jfma.2015.02.003","article-title":"A disease of reemerging importance","volume":"114","author":"Sridhar","year":"2015","journal-title":"J Formosan Med Assoc = Taiwan yi zhi"},{"key":"10.1016\/j.coviro.2018.10.001_bib0035","first-page":"e15618","article-title":"Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia","volume":"14","author":"Geng","year":"2014","journal-title":"Hepat Month"},{"key":"10.1016\/j.coviro.2018.10.001_bib0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijgo.2003.11.018","article-title":"Hepatitis E in pregnancy","volume":"85","author":"Kumar","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.coviro.2018.10.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1929","article-title":"Hepatitis E and pregnancy. Current state","author":"P\u00e9rez-Gracia","year":"2017","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1440-1746.2004.03437.x","article-title":"Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area","volume":"19","author":"Khuroo","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0055","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1537-2995.2008.01722.x","article-title":"A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route","volume":"48","author":"Matsubayashi","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.coviro.2018.10.001_bib0060","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1537-2995.2004.03300.x","article-title":"Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan","volume":"44","author":"Matsubayashi","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.coviro.2018.10.001_bib0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00535-003-1292-7","article-title":"Three male patients with sporadic acute hepatitis E in Sendai, Japan, who were domestically infected with hepatitis E virus of genotype III or IV","volume":"39","author":"Yamamoto","year":"2004","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0070","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.3748\/wjg.v22.i31.7030","article-title":"Hepatitis E. Discovery, global impact, control and cure","volume":"22","author":"Khuroo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(14)61034-5","article-title":"Hepatitis E virus in blood components. A prevalence and transmission study in southeast England","volume":"384","author":"Hewitt","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coviro.2018.10.001_bib0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/trf.12121","article-title":"Seroprevalence and incidence of hepatitis E virus infection in German blood donors","volume":"54","author":"Juhl","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.coviro.2018.10.001_bib0085","series-title":"Hepatitis E fact sheet","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.coviro.2018.10.001_bib0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1128\/CMR.00057-13","article-title":"Hepatitis E virus infection","volume":"27","author":"Kamar","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coviro.2018.10.001_bib0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2016.02.045","article-title":"Update on hepatitis E virology. Implications for clinical practice","volume":"65","author":"Debing","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/TP.0b013e3181c4096c","article-title":"Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation","volume":"89","author":"Kamar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2018.10.001_bib0105","doi-asserted-by":"crossref","first-page":"872431","DOI":"10.1155\/2015\/872431","article-title":"Mystery of hepatitis e virus. Recent advances in its diagnosis and management","volume":"2015","author":"Ahmed","year":"2015","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/lt.21958","article-title":"Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients","volume":"16","author":"Pischke","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.coviro.2018.10.001_bib0115","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jhep.2014.08.047","article-title":"The impact of hepatitis E in the liver transplant setting","volume":"61","author":"Behrendt","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0120","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/lt.22014","article-title":"Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b","volume":"16","author":"Haagsma","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.coviro.2018.10.001_bib0125","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfq282","article-title":"Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient","volume":"25","author":"Kamar","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coviro.2018.10.001_bib0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.12491","article-title":"Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection","volume":"23","author":"Zhou","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2018.10.001_bib0135","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.02427-15","article-title":"Antiviral activities of different interferon types and subtypes against hepatitis E virus replication","volume":"60","author":"Todt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.10.001_bib0140","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/hep.25530","article-title":"Suppression of interferon-\u03b1 signaling by hepatitis E virus","volume":"55","author":"Dong","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.coviro.2018.10.001_bib0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/fvl.15.17","article-title":"New insights into hepatitis E virus virus\u2013host interaction. Interplay with host interferon induction","volume":"10","author":"Wu","year":"2015","journal-title":"Future Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/vim.2015.0107","article-title":"ORF3 of hepatitis E virus inhibits the expression of proinflammatory cytokines and chemotactic factors in LPS-stimulated human PMA-THP1 cells by inhibiting NF-\u03baB pathway","volume":"29","author":"Lei","year":"2016","journal-title":"Viral Immunol"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0155","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","article-title":"Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection","volume":"139","author":"Kamar","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-153-2-201007200-00257","article-title":"Brief communication. Case reports of ribavirin treatment for chronic hepatitis E","volume":"153","author":"Mallet","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2018.10.001_bib0165","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/liv.12114","article-title":"Ribavirin treatment of acute and chronic hepatitis E. A single-centre experience","volume":"33","author":"Pischke","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.coviro.2018.10.001_bib0170","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"New England J Med"},{"key":"10.1016\/j.coviro.2018.10.001_bib0175","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcv.2014.05.003","article-title":"Severe acute hepatitis E in an HIV infected patient. Successful treatment with ribavirin","volume":"60","author":"Robbins","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.antiviral.2013.12.005","article-title":"Antiviral strategies for hepatitis E virus","volume":"102","author":"Debing","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2018.10.001_bib0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0190","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.coviro.2011.10.030","article-title":"Ribavirin for the treatment of chronic hepatitis C virus infection. A review of the proposed mechanisms of action","volume":"1","author":"Paeshuyse","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0195","doi-asserted-by":"crossref","DOI":"10.3390\/v8100283","article-title":"Mutagenic effects of ribavirin on hepatitis E virus-viral extinction versus selection of fitness-enhancing mutations","volume":"8","author":"Todt","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.10.001_bib0200","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1128\/JVI.76.17.8505-8517.2002","article-title":"Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system","volume":"76","author":"Contreras","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0205","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1128\/JVI.75.17.8074-8081.2001","article-title":"Ribavirin induces error-prone replication of gb virus B in primary tamarin hepatocytes","volume":"75","author":"Lanford","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/JVI.77.1.481-488.2003","article-title":"Ribavirin causes error catastrophe during Hantaan virus replication","volume":"77","author":"Severson","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0215","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/JVI.01606-06","article-title":"Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin. Implications for error catastrophe","volume":"81","author":"Sierra","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0220","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virusres.2004.11.007","article-title":"Ribavirin and lethal mutagenesis of poliovirus. Molecular mechanisms, resistance and biological implications","volume":"107","author":"Vignuzzi","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0225","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","article-title":"In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome","volume":"65","author":"Todt","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0230","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2016.05.002","article-title":"Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity","volume":"65","author":"Debing","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0235","series-title":"Quasispecies: From Theory to Experimental Systems","year":"2016"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol Mol Biol Rev MMBR"},{"key":"10.1016\/j.coviro.2018.10.001_bib0245","doi-asserted-by":"crossref","first-page":"e1001005","DOI":"10.1371\/journal.ppat.1001005","article-title":"Quasispecies theory and the behavior of RNA viruses","volume":"6","author":"Lauring","year":"2010","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.coviro.2018.10.001_bib0250","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/infdis\/jit438","article-title":"Influence of polyproline region and macro domain genetic heterogeneity on HEV persistence in immunocompromised patients","volume":"209","author":"Lhomme","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0255","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1128\/JVI.01003-12","article-title":"Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients","volume":"86","author":"Lhomme","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0260","series-title":"Quasispecies. Quasispecies: From Theory to Experimental Systems","first-page":"161","article-title":"Theories of Lethal Mutagenesis. From Error Catastrophe to Lethal Defection","author":"Tejero","year":"2016"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0265","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2014.08.040","article-title":"A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients","volume":"147","author":"Debing","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.001_bib0270","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/AAC.02496-15","article-title":"Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy","volume":"60","author":"Lhomme","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.10.001_bib0275","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/TP.0000000000001908","article-title":"Summary of the british transplantation society UK guidelines for hepatitis E and solid organ transplantation","volume":"102","author":"McPherson","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2018.10.001_bib0285","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/j.1600-6143.2012.04200.x","article-title":"Chronic hepatitis e in heart transplant recipients","volume":"12","author":"Pischke","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2018.10.001_bib0290","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1093\/nar\/gkt1106","article-title":"RNA-dependent RNA polymerase of Japanese encephalitis virus binds the initiator nucleotide GTP to form a mechanistically important pre-initiation state","volume":"42","author":"Surana","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2018.10.001_bib0295","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1505.081100","article-title":"Virulent strain of hepatitis E virus genotype 3, Japan","volume":"15","author":"Takahashi","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.001_bib0300","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/liv.12911","article-title":"Treatment of autochthonous acute hepatitis E with short-term ribavirin. A multicenter retrospective study","volume":"36","author":"P\u00e9ron","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.coviro.2018.10.001_bib0305","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1099\/vir.0.049577-0","article-title":"Early secretory pathway localization and lack of processing for hepatitis E virus replication protein pORF1","volume":"94","author":"Perttil\u00e4","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0310","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1128\/JVI.01219-07","article-title":"Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles","volume":"82","author":"Graff","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0315","doi-asserted-by":"crossref","first-page":"22759","DOI":"10.1074\/jbc.M200185200","article-title":"The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2","volume":"277","author":"Tyagi","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2018.10.001_bib0320","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/JVI.79.2.1017-1026.2005","article-title":"In vitro and in vivo mutational analysis of the 3\u2032-terminal regions of hepatitis E virus genomes and replicons","volume":"79","author":"Graff","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0325","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.gene.2015.01.033","article-title":"The intergenic-junction variant (genotype 2 isolate) of hepatitis E virus restores the CREX\u2019 stem-loop\u2019 structural integrity, essential for viral life cycle","volume":"559","author":"Parvez","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.coviro.2018.10.001_bib0330","doi-asserted-by":"crossref","first-page":"15270","DOI":"10.1073\/pnas.251555098","article-title":"Recombinant hepatitis E virus genomes infectious for primates. Importance of capping and discovery of a cis-reactive element","volume":"98","author":"Emerson","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.coviro.2018.10.001_bib0335","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1099\/vir.0.051870-0","article-title":"An essential RNA element resides in a central region of hepatitis E virus ORF2","volume":"94","author":"Emerson","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0340","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1128\/JVI.79.11.6680-6689.2005","article-title":"The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques","volume":"79","author":"Graff","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0345","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.00146-12","article-title":"Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination","volume":"86","author":"Shukla","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_sbref0350","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1073\/pnas.1018878108","article-title":"Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant","volume":"108","author":"Shukla","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.10.001_bib0355","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1099\/vir.0.037259-0","article-title":"A naturally occurring human\/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture","volume":"93","author":"Nguyen","year":"2012","journal-title":"J General Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0360","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jvh.12157","article-title":"An ORF1-rearranged hepatitis E virus derived from a chronically infected patient efficiently replicates in cell culture","volume":"21","author":"Johne","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2018.10.001_bib0365","doi-asserted-by":"crossref","first-page":"12017","DOI":"10.1128\/JVI.01625-14","article-title":"Characterization of the polyproline region of the hepatitis E virus in immunocompromised patients","volume":"88","author":"Lhomme","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0370","doi-asserted-by":"crossref","first-page":"e0124396","DOI":"10.1371\/journal.pone.0124396","article-title":"Identification and fine mapping of nuclear and nucleolar localization signals within the human ribosomal protein S17","volume":"10","author":"Kenney","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.10.001_bib0375","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/341491a0","article-title":"Ubiquitin in a togavirus","volume":"341","author":"Meyers","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.10.001_bib0380","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/340156a0","article-title":"Increased viral pathogenicity after insertion of a 28S ribosomal RNA sequence into the haemagglutinin gene of an influenza virus","volume":"340","author":"Khatchikian","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.10.001_bib0385","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1074\/jbc.M412684200","article-title":"Viral RNA-directed RNA polymerases use diverse mechanisms to promote recombination between RNA molecules","volume":"280","author":"Chetverin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2018.10.001_bib0390","doi-asserted-by":"crossref","first-page":"8958","DOI":"10.1128\/JVI.73.11.8958-8965.1999","article-title":"Nonreplicative RNA recombination in poliovirus","volume":"73","author":"Gmyl","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","article-title":"Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin","volume":"150","author":"Dao Thi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.001_bib0400","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jhep.2016.09.014","article-title":"Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection","volume":"66","author":"van der Valk","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.001_bib0405","first-page":"318","article-title":"HCV and HEV recurrence after liver transplantation. One antiviral therapy for two viruses","volume":"30","author":"Martin","year":"2017","journal-title":"TranspInternational"},{"key":"10.1016\/j.coviro.2018.10.001_bib0410","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.gastro.2016.05.060","article-title":"Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV\/HCV co-infected liver transplant recipient","volume":"152","author":"Donnelly","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:00:37Z","timestamp":1761818437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718300191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":82,"alternative-id":["S1879625718300191"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.10.001","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}